Loading...
•
Sep 30, 2020
Baxter Q3 2020 Earnings Report
Baxter's Q3 2020 performance reflected ongoing demand and resilience amid a public health crisis.
Key Takeaways
Baxter International Inc. reported a 4% increase in worldwide sales, totaling $2.97 billion. U.S. GAAP earnings per share (EPS) decreased 3% to $0.69, while adjusted EPS increased 12% to $0.83.
Worldwide sales increased 4% on a reported and constant currency basis.
U.S. GAAP earnings per share decreased 3% to $0.69.
Adjusted EPS increased 12% to $0.83.
Baxter expects full-year 2020 low single digit sales growth on a reported, constant currency and operational basis.
Baxter
Baxter
Baxter Revenue by Geographic Location
Revenue by Geographic Location
United States Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
Baxter expects full-year 2020 sales growth to be up low single digits on a reported, constant currency and operational basis. The company expects U.S. GAAP earnings of $2.41 to $2.44 per share and adjusted earnings of $3.02 to $3.05 per share.
Positive Outlook
- Sales growth expected to be up low single digits.
- U.S. GAAP earnings expected between $2.41 and $2.44 per share.
- Adjusted earnings expected between $3.02 and $3.05 per share.
- The company continues to innovate and receive regulatory approvals for new products.
- Baxter is committed to corporate responsibility and workplace excellence.
Challenges Ahead
- Outlook assumes low double-digit declines in hospital admissions.
- Outlook assumes mid-single digit declines in surgical volumes.
- Sales in Medication Delivery and Pharmaceuticals are impacted by lower rates of emergency room utilization.
- Hospital admissions and surgical procedures in the U.S. declined as compared to pre-COVID levels.
- The company faces risks related to demand, market acceptance, product development, and global economic conditions.
Revenue & Expenses
Visualization of income flow from segment revenue to net income